Bristol-Myers buys into Summit's Seglin tech

Fresh from its $2.5 billion debacle on the hepatitis C front, Bristol-Myers Squibb ($BMY) is putting up a modest $100,000 fee to gain access to Summit Corp.'s Seglin technology, which promises a new approach to diseases like Alzheimer's. But BMS says that if the U.K. biotech's technology works out, it's willing to pay up to $30 million for each successful new program to make its way through the clinic. Summit CEO Glyn Edwards tells Proactive Investors that Bristol will explore up to 10 drug targets. Story

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.